DIAMYD MEDICAL LICENSES NOVEL PAIN PRODUCT.Diamyd Medical has acquired an exclusive license for Endomorphin technology that may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes. "In addition to this newly acquired Endomorphin technology, and our exclusive licenses for GAD Gad, in the Bible, son of Jacob and Zilpah and eponymous founder of one of the 12 tribes of Israel. Its allotment was half of Gilead; this was the land best suited to the pastoral life, which Gad, like Reuben, continued after the years in Egypt. , we also have an ongoing clinical development program with Enkephalin enkephalin (ĕnkĕf`əlĭn), one of several naturally occurring morphinelike substances (endorphins) released from nerve endings of the central nervous system and the adrenal medulla. ," saidsays Elisabeth Lindner, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Diamyd Medical. With Enkephalin, GAD and Endomorphin, we have completed our pain portfolio now having products targeting all three major pain receptors. This gives us a strong position in the development of products for multiple pain types, including neuropathic pain that alone has a market potential estimated to more than 3.5 billion dollars." The Endomorphin technology embodies a direct production and release of Endomorfin peptides with morphine-like activity directly into the spinal cord spinal cord, the part of the nervous system occupying the hollow interior (vertebral canal) of the series of vertebrae that form the spinal column, technically known as the vertebral column. blocking further pain signal generation. Morphine has been used for centuries to provide pain relief and continues to be an essential tool in modern clinical pain management. However, in addition to pain relief, Morphine produces a host of undesirable side effects Side effects Effects of a proposed project on other parts of the firm. . "The newly licensed technology allows focal delivery of Endomorphin directly to the site of pain using our NTDDS (Nerve Targeting Drug Delivery system) platform. The localized Endomorphin delivery is not expected to have side effects like systemic Morphine," states Darren Wolfe, President of Diamyd Inc, Pittsburgh, USA. Diamyd Inc, Pittsburgh, PA, USA, is a fully owned subsidiary of Diamyd Medical and is a leader in the field of drug delivery to the nervous system. The Endomorphin technology has been the subject to two peer-reviewed publications including; "Engineering an Endomorphin-2 gene for use in neuropathic pain therapy" in Pain, 2007, 133:29-38 and "Effects of transgene-mediated Endomorphin-2 in inflammatory pain" in Eur J Pain, 2008 Epub. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd(r) for type 1 diabetes type 1 diabetes n. See diabetes mellitus. for which Phase III trials are ongoing in both the U.S. and Europe. Furthermore, the company has ongoing clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. Diamyd Medical has offices in Sweden and in the U.S. The share is quoted on the OMX OMX Office Max (stock symbol) Stockholm Nordic Exchange (Stockholm:DIAM B) and on OTCQX in the U.S. (Pink Sheets:DMYDY) administered by the Pink Sheets and the Bank of New York The Bank of New York, abbrieviated to BNY, was a global financial services company that existed until its merger with the Mellon Financial Corporation on July 2, 2007.[1] The bank now continues under the new name of The Bank of New York Mellon Corporation. (PAL). For more information, visit http://www.diamyd.com or call 412/770-1310. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion